ARTICLE | Company News
Altos Therapeutics, Takeda deal
July 18, 2016 7:00 AM UTC
The companies partnered to develop Altos’ sole asset, ATC-1906. As part of the deal, Takeda received an option to acquire Altos. The partners plan to develop the oral dopamine D2 and D3 receptor anta...